Lymphatic filariasis endgame strategies: Using GEOFIL to model mass drug administration and targeted surveillance and treatment strategies in American Samoa

被引:2
|
作者
Shaw, Callum [1 ]
McLure, Angus [1 ]
Graves, Patricia [2 ]
Lau, Colleen [3 ]
Glass, Kathryn [1 ]
机构
[1] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia
[2] James Cook Univ, Coll Publ Hlth Med & Vet Sci, Cairns, Qld, Australia
[3] Univ Queensland, Fac Med, Sch Publ Hlth, Brisbane, Qld, Australia
来源
PLOS NEGLECTED TROPICAL DISEASES | 2023年 / 17卷 / 05期
基金
英国医学研究理事会; 澳大利亚研究理事会;
关键词
WUCHERERIA-BANCROFTI; TRANSMISSION; ELIMINATION; PROGRAM;
D O I
10.1371/journal.pntd.0011347
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
American Samoa underwent seven rounds of mass drug administration (MDA) for lymphatic filariasis (LF) from 2000-2006, but subsequent surveys found evidence of ongoing transmission. American Samoa has since undergone further rounds of MDA in 2018, 2019, and 2021; however, recent surveys indicate that transmission is still ongoing. GEOFIL, a spatially-explicit agent-based LF model, was used to compare the effectiveness of territory-wide triple-drug MDA (3D-MDA) with targeted surveillance and treatment strategies. Both approaches relied on treatment with ivermectin, diethylcarbamazine, and albendazole. We simulated three levels of whole population coverage for 3D-MDA: 65%, 73%, and 85%, while the targeted strategies relied on surveillance in schools, workplaces, and households, followed by targeted treatment. In the household-based strategies, we simulated 1-5 teams travelling village-to-village and offering antigen (Ag) testing to randomly selected households in each village. If an Ag-positive person was identified, treatment was offered to members of all households within 100m-1km of the positive case. All simulated interventions were finished by 2027 and their effectiveness was judged by their 'control probability'-the proportion of simulations in which microfilariae prevalence decreased between 2030 and 2035. Without future intervention, we predict Ag prevalence will rebound. With 3D-MDA, a 90% control probability required an estimated >= 4 further rounds with 65% coverage, >= 3 rounds with 73% coverage, or >= 2 rounds with 85% coverage. While household-based strategies were substantially more testing-intensive than 3D-MDA, they could offer comparable control probabilities with substantially fewer treatments; e.g. three teams aiming to test 50% of households and offering treatment to a 500m radius had approximately the same control probability as three rounds of 73% 3D-MDA, but used < 40% the number of treatments. School- and workplace-based interventions proved ineffective. Regardless of strategy, reducing Ag prevalence below the 1% target threshold recommended by the World Health Organization was a poor indicator of the interruption of LF transmission, highlighting the need to review blanket elimination targets. Author summaryLymphatic filariasis (LF) is a parasitic disease caused by infection with filarial worms and is currently endemic in 72 countries. Mass drug administration (MDA) is used to interrupt LF transmission, in order to reduce LF prevalence below a target threshold set by the World Health Organization. When prevalence is below said threshold, continued LF transmission is believed to be unsustainable. American Samoa implemented seven rounds of MDA from 2000-2006 and, more recently, a further three rounds of MDA in 2018, 2019, and 2021. Despite these recent interventions, American Samoa has not yet reached elimination targets. In this study we use GEOFIL, a LF transmission model specific to American Samoa, to investigate the most efficient interventions for LF elimination-whether to continue with MDA or instead try targeted surveillance and treatment strategies. We find that, without further intervention, LF prevalence will rise, but further rounds of MDA have the potential to eliminate LF. Household-focused targeted surveillance and treatment interventions also have the ability to eliminate LF using far fewer treatments than MDA; however, they require testing a large number of people. Furthermore, we found that reducing antigen prevalence below threshold targets does not necessarily guarantee successful long-term elimination.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Factors associated with never treatment and acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana, 2021
    Duguay, Claudia
    Niles-Robin, Reza A.
    Thickstun, Charles R.
    Cox, Horace
    Sampson, Annastacia
    Alexandre, Jean Seme-Fils
    Caleb-Mars, Nathely
    Goss, Charles W.
    Morice, Ana
    Scholte, Ronaldo G. Carvalho
    Krentel, Alison
    PLOS GLOBAL PUBLIC HEALTH, 2024, 4 (04):
  • [42] A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018
    Willis, Gabriela A.
    Mayfield, Helen
    Kearns, Therese
    Naseri, Take
    Thomsen, Robert
    Gass, Katherine
    Sheridan, Sarah
    Graves, Patricia M.
    Lau, Colleen L.
    PLOS NEGLECTED TROPICAL DISEASES, 2020, 14 (11): : 1 - 18
  • [43] How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?
    Kura, Klodeta
    Stolk, Wilma A.
    Basanez, Maria-Gloria
    Collyer, Benjamin S.
    de Vlas, Sake J.
    Diggle, Peter J.
    Gass, Katherine
    Graham, Matthew
    Hollingsworth, T. Deirdre
    King, Jonathan D.
    Krentel, Alison
    Anderson, Roy M.
    Coffeng, Luc E.
    CLINICAL INFECTIOUS DISEASES, 2024, 78 : S93 - S100
  • [44] A mathematical model for long-term effect of diethylcarbamazine-albendazole mass drug administration on lymphatic filariasis
    Tasman, H.
    Supali, T.
    Supriatna, A. K.
    Nuraini, N.
    Soewono, E.
    SYMPOSIUM ON BIOMATHEMATICS, 2015, 1651 : 138 - 146
  • [45] USING STORIES TO SUPPORT MASS DRUG ADMINISTRATION ELIMINATION OF LYMPHATIC FILARIASIS IN AGAM DISTRICT AND DEPOK CITY, INDONESIA
    Krentel, Alison
    Damayanti, Rita
    Titaley, Christiana R.
    Soeharno, Nugroho
    Bradley, Mark H.
    Lynam, Timothy
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2015, 93 (04): : 409 - 410
  • [46] THE IMPACT OF MASS DRUG ADMINISTRATION WITH A TRIPLE DRUG REGIMEN (IVERMECTIN, DIETHYLCARBAMAZINE AND ALBENDAZOLE) ON LYMPHATIC FILARIASIS IN PAPUA NEW GUINEA AND IMPLICATIONS FOR POST-MDA SURVEILLANCE
    Bun, Krufinta
    Laman, Moses
    Susapu, Melinda
    Sekihara, Makoto
    Giorgi, Emanuele
    Diggle, Peter J.
    Payne, Michael
    Tisch, Daniel
    Bjerum, Catherine
    Mode, Benedict
    Robinson, Leanne
    Weil, Gary
    King, Christopher L.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2021, 105 (05): : 138 - 138
  • [47] A biological model of scabies infection dynamics and treatment informs mass drug administration strategies to increase the likelihood of elimination
    Lydeamore, M. J.
    Campbell, P. T.
    Regan, D. G.
    Tong, S. Y. C.
    Andrews, R. M.
    Steer, A. C.
    Romani, L.
    Kaldor, J. M.
    McVernon, J.
    McCaw, J. M.
    MATHEMATICAL BIOSCIENCES, 2019, 309 : 163 - 173
  • [48] What is needed to eradicate lymphatic filariasis? A model-based assessment on the impact of scaling up mass drug administration programs
    Kastner, R.
    Stone, C.
    Steinmann, P.
    Tediosi, F.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2015, 20 : 229 - 229
  • [49] What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs
    Kastner, Randee J.
    Stone, Christopher M.
    Steinmann, Peter
    Tanner, Marcel
    Tediosi, Fabrizio
    PLOS NEGLECTED TROPICAL DISEASES, 2015, 9 (10):
  • [50] Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach
    Njomo, Doris W.
    Kibe, Lydiah W.
    Kimani, Bridget W.
    Okoyo, Collins
    Omondi, Wyckliff P.
    Sultani, Hadley M.
    PLOS NEGLECTED TROPICAL DISEASES, 2020, 14 (09): : 1 - 22